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In most countries, medicines have a product licence that describes how they should be used. 
Licencing is intended to assure that medicines meet acceptable standards of efficacy, safety and 
quality for a particular indication in a particular group of patients.1 ‘Off-label’ use occurs when a drug 
is prescribed for an unlicensed indication, to an unlicensed patient group (e.g. children), and/or as an 
unlicensed dosage or formulation. In the linked paper, Wong and colleagues found that almost a 
third of antidepressants were prescribed for off-label indications, most commonly pain, insomnia 
and migraine.2 
 
Physicians can legally prescribe off-label, and professional licencing agencies recognise that off-label 
use is necessary if licenced medicines are ineffective, are associated with adverse effects, or if the 
licenced dose or formulation do not meet the patient’s needs. Professional responsibility in these 
circumstances is fundamentally the same as for on-label prescribing. As the United Kingdom medical 
regulator says: “We expect you to carefully consider any treatment that you prescribe, and we 
expect you to be able to justify your decisions and actions when prescribing, administering and 
managing medicines regardless of whether they are licensed or unlicensed.”3 Although off-label 
prescribing may need more explicit justification, the evidence supporting prescribing is actually more 
important rather than the licence per se.  
 
Only 16% of the off-label prescribing identified by Wong and colleagues was directly supported by 
strong evidence, with a further 40% having indirect support from strong evidence for other drugs in 
the same class.2 Although it may seem odd that off-label prescribing can have strong evidence, this 
frequently occurs when new indications for old drugs are evaluated in trials, but pharmaceutical 
companies have not judged it worthwhile to alter existing marketing authorisations because the 
drug is off-patent and the required regulatory process is complex and expensive. Amitriptyline use 
for chronic pain is an example of evidence-based4 and guideline recommended off-label prescribing5 
and accounted for 14% of off-label antidepressant prescribing in the linked study.2 Extending the 
range of uses of long-established medicines like this way is attractive for health care professionals 
and patients alike, because they are perceived to have familiar safety-profiles and are cheaper. 
Similarly, clinical guidelines may recommend antidepressant drug classes for extended indications 
like anxiety rather than only specific licenced medicines,6 even though this requires a fairly strong 
assumption that all drugs in the same class are equally effective or equally safe.  
 
Clinical and shared decision-making is complicated by these mismatches between licencing, evidence 
and guidelines within countries, further confused by licencing and guidelines varying between 
different countries, even to the point of inconsistency in which adverse drug events are considered 
significant for licenced drugs.7 For all prescribing, patients (or their parents or carers) should be 
provided with enough information to allow them to make an informed decision to take a medicine 
(or not). This should include whether the intended use is off-label, but more importantly should 
account for the evidence base underlying the prescriber’s recommendation.3 How often this occurs 
in practice remains uncertain. Electronic prescribing systems offer opportunities to provide more 
point-of-care information to prescribers and patients, including whether an intended use is off-label 
and/or lacks evidence in the patient in front of them. However, such systems need careful design 
and evaluation to avoid unintended consequences of implementation in time-constrained clinical 
workflows. 
 
Off-label prescribing matters because it is usually (but not always) associated with significant 
uncertainty about the balance of benefit and harm.8 Prescribers should therefore be cautious when 
they prescribe an off-label medicine based on an extrapolation of evidence for a different indication, 
in a different patient group, and/or for a significantly different dose or formulation. Equally though, 
on-label prescribing also often involves extrapolation, most commonly because the patient in front 
of the prescriber is very different from the patients included in trials. For example, on-label use of 
antidepressants to treat depression is based on trials carried out in people with more severe 
depression and less psychiatric and physical comorbidity than is typical in everyday practice.9,10 As a 
result, most people with well-characterised Major Depressive Disorder in everyday practice would 
be ineligible for the antidepressant treatment trials on which licencing and treatment 
recommendations are based.11 There is also evidence that those ineligible for trials are less likely to 
respond to antidepressants and more likely to experience adverse events.12 Off-label prescribing 
clearly matters because it often lacks any strong evidence or relies on extrapolating evidence from 
one situation to another, but prescribers and patients should be cautious about all extrapolations of 
evidence whether on- or off-label.  
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